X

Trial Profile

A Phase I Clinical Trial to Evaluate AS1411-GNP for the Treatment of Acute Myeloid Leukemia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QN 247 (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions
Sponsors Qualigen Therapeutics

Most Recent Events

22 Dec 2020 According to a Qualigen Therapeutics media release, the company plans to file an IND for ALAN and subsequently initiate this phase 1 trial for the treatment of AML in the second half of calendar 2021.
13 Nov 2020 According to a Qualigen Therapeutics media release, University of Louisville (UofL) will perform preclinical studies on acute myeloid leukemia and the company aims to file an IND and initiate this Phase 1 clinical trial later in calendar year 2021.
26 May 2020 According to an Qualigen media release, ALAN is expected to begin Phase I clinical trials for cancer in 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com